Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Leases (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Current Leases for 6 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 56.83% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 56.83% year-over-year, with the annual reading at $7.2 million for FY2025, 56.83% up from the prior year.
  • Current Leases for Q4 2025 was $7.2 million at TScan Therapeutics, up from $6.9 million in the prior quarter.
  • The five-year high for Current Leases was $7.2 million in Q4 2025, with the low at $1.6 million in Q2 2021.
  • Average Current Leases over 5 years is $3.7 million, with a median of $3.7 million recorded in 2022.
  • The sharpest move saw Current Leases skyrocketed 143.79% in 2023, then fell 14.14% in 2024.
  • Over 5 years, Current Leases stood at $1.7 million in 2021, then surged by 122.96% to $3.7 million in 2022, then decreased by 11.82% to $3.2 million in 2023, then skyrocketed by 40.79% to $4.6 million in 2024, then skyrocketed by 56.83% to $7.2 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $7.2 million, $6.9 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.